Motion correction has potential to affect diagnosis or patient care.
There was better quantification and detection of PET-avid lesions with the addition of a motion correction algorithm, according to a study published in the Journal of Nuclear Medicine.
Researchers from the United Kingdom sought to determine the ability of their joint PET/MRI-based predictive motion model to correct respiratory motion in PET, demonstrating that the algorithm could improve lesion detectability and quantitation and reduce image artifacts.
Forty-two clinical PET/MRI patient datasets containing 162 PET-avid lesions were included in the study. The researchers used multiple tracers and multiple organ locations to apply their motion correction method to the datasets. Quantitative changes were calculated using SUV changes in avid lesions. Lesion detectability changes were explored with a study; two radiologists identified lesions in uncorrected and motion-corrected images and provided confidence scores.
The results showed mean increases of 12.4% for SUVpeak and 17.6% for SUVmax after motion correction were found. In the detectability study, confidence scores for detecting avid lesions increased, with a rise in mean score from 2.67 to 3.01 (of 4) after motion correction and a rise in detection rate from 74% to 84%. Of 162 confirmed lesions, 49 showed an increase in all three metrics-SUVpeak, SUVmax, and combined reader confidence score-whereas only two lesions showed a decrease.
The researchers also presented clinical case studies that demonstrated the effect of respiratory motion correction of PET data on patient management, with increased numbers of detected lesions, improved lesion sharpness and localization, and reduced attenuation-based artifacts.
They concluded that there were significant improvements in quantification and detection of PET-avid lesions, with specific case study examples showing where motion correction has the potential to affect diagnosis or patient care.
FDA Clears Magnetic Resonance Spectroscopy Platform for Non-Invasive Assessment of Brain Chemistry
November 29th 2023BrainSpec Core reportedly offers enhanced sensitivity for low-grade gliomas and may facilitate the diagnosis of conditions including Alzheimer’s disease, multiple sclerosis, and epilepsy.
Study Says Contrast-Enhanced Mammography Offers Comparable Breast Cancer Detection to MRI
November 15th 2023In findings from an enriched cohort of asymptomatic patients with screening-detected abnormalities, researchers found that contrast-enhanced mammography (CEM) was superior to conventional mammography and offered equivalent detection of breast cancer in comparison to breast MRI and abbreviated breast MRI.
Adjunctive Brain Volume Quantification Tool for MRI Gets FDA Clearance
November 14th 2023Providing automated brain volume calculations based on MRI images, NeuroShield’s artificial intelligence (AI)-powered technology may help facilitate treatment for neurodegenerative conditions ranging from Alzheimer’s disease to epilepsy.